Btk Inhibitor Selective Platelet Aggregation Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antithrombotic therapies, such as dual anti-platelet therapy with aspirin and P2Y12 antagonists, are limited in efficacy for preventing atherothrombosis and are associated with an increased bleeding risk, as they affect both plaque-triggered platelet activation and physiologic hemostasis.
Innovation Solution
Development of a Btk inhibitor, specifically targeting Bruton's tyrosine kinase, which selectively inhibits platelet activation pathways triggered by collagen and von Willebrand factor, thereby reducing platelet aggregation and thrombus formation without affecting normal hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual anti-platelet therapy with aspirin and P2Y12 antagonists is used, then platelet activation is inhibited, but bleeding risk increases
Solution Approach 1:
The patent segments the anti-platelet therapy mechanism by specifically targeting the GPVI signaling pathway through Btk inhibition, rather than using broad-spectrum anti-platelet agents. This selective segmentation allows inhibition of plaque-triggered platelet activation while preserving other hemostatic pathways, thereby reducing bleeding risk compared to dual anti-platelet therapy
Solution Approach 2:
The invention applies local quality by designing a therapy that selectively acts on platelet activation triggered by atherosclerotic plaque (through collagen-GPVI-Btk pathway) while leaving normal physiological hemostasis intact. The Btk inhibitor specifically disrupts the pathological signaling cascade in plaque-induced thrombosis without broadly suppressing all platelet functions
2Reliability
If dual anti-platelet therapy is used, then some atherothrombosis prevention is achieved, but efficacy is limited
Solution Approach 1:
The patent introduces Btk as a key intermediary in the GPVI signaling pathway that mediates platelet activation by collagen and plaque material. By specifically inhibiting Btk, the therapy intercepts and blocks the signaling cascade at a critical intermediate step, providing more effective prevention of atherothrombosis compared to therapies that act on upstream or downstream targets
Solution Approach 2:
The invention changes the therapeutic parameter from broad platelet inhibition to specific pathway inhibition by targeting Btk kinase activity. This parameter change from non-specific to specific inhibition enhances therapeutic efficacy by precisely disrupting the collagen-GPVI-Btk signaling axis that drives plaque-induced thrombosis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Btk inhibitor effectively prevents atherothrombosis by selectively inhibiting plaque-induced platelet aggregation under arterial flow conditions while minimizing bleeding risks, offering a more efficient and safer alternative to standard therapies.
Implementation Method 1
Development of a Btk inhibitor, specifically targeting Bruton's tyrosine kinase, which selectively inhibits platelet activation pathways triggered by collagen and von Willebrand factor
Data Source
Figure 1A
Figure 1B
Figure 1C~1D
AI summary
The present invention relates to an inhibitor of Bruton's tyrosine kinase (Btk) for use in the treatment and/or prevention of atherothrombosis. The present invention further relates to a method of treating and/or preventing atherothrombosis comprising administering a pharmaceutically effective amount of an inhibitor of Bruton's tyrosine kinase (Btk) to a subject in need thereof.